ORTHO-EST
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORTHO-EST (ORTHO-EST).
Estradiol is a steroid hormone that binds to and activates estrogen receptors (ERα and ERβ), leading to regulation of gene transcription and modulation of various physiological processes including reproductive function, bone metabolism, and cardiovascular health.
| Metabolism | Primarily hepatic via CYP3A4; undergoes enterohepatic recirculation; metabolites include estrone, estriol, and conjugates. |
| Excretion | Renal elimination (90-95%) as glucuronide and sulfate conjugates; fecal (5-10%) via biliary excretion. |
| Half-life | 12-18 hours (terminal elimination half-life); clinical context: dosed once daily, steady-state achieved in 5-7 days. |
| Protein binding | 50-80% bound to albumin and sex hormone-binding globulin (SHBG); binding to SHBG is approx. 30-50%. |
| Volume of Distribution | 1-2 L/kg; clinical meaning: extensive distribution into tissues, including fat and reproductive organs. |
| Bioavailability | Oral: 40-60% due to first-pass metabolism; transdermal: approximately 10-20% systemic availability (not primary route). |
| Onset of Action | Oral: 2-4 hours for symptom relief (e.g., vasomotor symptoms). |
| Duration of Action | 24 hours after a single oral dose; clinical notes: daily dosing required for continuous effect. |
| Molecular Weight | 436.54 Da (estropipate; estrone sulfate piperazine salt) |
1.25 mg orally once daily for 21 days, followed by 7 days off; or 0.625 mg orally once daily continuously.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Severe renal impairment (GFR <30 mL/min): use with caution due to potential accumulation of conjugated estrogens. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: contraindicated due to impaired estrogen metabolism. |
| Pediatric use | Not indicated for use in pediatric patients. |
| Geriatric use | Initiate at lowest effective dose (0.625 mg orally once daily) and titrate cautiously due to increased risk of thromboembolic events and endometrial cancer. |
| 1st trimester | Crosses placenta; associated with increased risk of fetal reproductive tract abnormalities, cardiovascular defects, and limb reduction defects. Avoid use during first trimester. |
| 2nd trimester | Fetal exposure may increase risk of genital tract abnormalities and other developmental issues. Use only if clearly needed and no alternative. |
| 3rd trimester | Fetal exposure may cause urogenital tract abnormalities and potential long-term carcinogenic risk. Use contraindicated. |
Clinical note
Comprehensive clinical and safety monograph for ORTHO-EST (ORTHO-EST).
| Placental transfer | Crosses placenta; fetal serum levels 10-20% of maternal levels. Therapeutic doses can cause fetal exposure. |
| Breastfeeding | Estropipate, conjugated estrogen, is excreted into breast milk in low concentrations. May reduce milk production and quality. Monitor infant for estrogenic effects (e.g., breast enlargement, vaginal bleeding). Limited clinical data; avoid use, especially in nursing mothers of preterm infants or high dose therapy. |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer in postmenopausal women with an intact uterus. They should not be used during pregnancy. There is an increased risk of cardiovascular events (e.g., stroke, myocardial infarction) and breast cancer with estrogen-alone therapy.
| Serious Effects |
Undiagnosed abnormal genital bleedingKnown or suspected pregnancyActive or history of thromboembolic disorders (e.g., DVT, PE)Active or history of arterial thromboembolic cardiovascular disease (e.g., stroke, MI)Known or suspected estrogen-dependent neoplasia (e.g., breast cancer, endometrial cancer)Hypersensitivity to estropipate or any componentKnown or current hepatic impairment or disease, including cholestatic jaundice
| Precautions | Cardiovascular disorders (thrombophlebitis, thromboembolism), malignancy (breast, endometrial), gallbladder disease, hypercalcemia, fluid retention, hepatic impairment, hypothyroidism, and hereditary angioedema. |
| Food/Dietary | Grapefruit juice may increase systemic exposure to esterified estrogens; avoid concurrent consumption. No other significant food interactions are documented. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - Limited data; potential for adverse effects in infant. |
| Teratogenic Risk | ORTHO-EST (estradiol) is a pregnancy category X drug. Use is contraindicated during pregnancy. First trimester exposure is associated with a risk of congenital anomalies (e.g., cardiovascular, limb defects, VACTERL association) based on epidemiological data. Second and third trimester exposure may cause fetal harm including urogenital tract abnormalities and potential carcinogenic effects. Estrogens are not recommended for use in pregnancy. |
| Fetal Monitoring | No specific monitoring is required because use is contraindicated in pregnancy. For accidental exposure, fetal ultrasound and echocardiography may be considered to assess for congenital anomalies. maternal blood pressure and liver function should be monitored if exposure occurs. |
| Fertility Effects | Estradiol can affect fertility by its mechanism as a contraceptive. It inhibits ovulation when used in combination with a progestin, but as a monotherapy, it may disrupt menstrual cycles and suppress ovulation. Return to fertility is expected upon discontinuation. However, prolonged use may delay conception. No permanent effects on fertility have been documented. |
| Clinical Pearls | ORTHO-EST (esterified estrogens) is indicated for moderate to severe vasomotor symptoms due to menopause and for prevention of postmenopausal osteoporosis. It carries a boxed warning for endometrial cancer in women with an intact uterus; co-administration with a progestin is required unless the patient has had a hysterectomy. Risk of venous thromboembolism is increased; avoid in patients with active VTE or history of VTE. Estrogen use may increase risk of breast cancer, especially with prolonged use (>5 years). Do not use in women with undiagnosed abnormal genital bleeding. Monitor for signs of hypercalcemia in patients with metastatic breast cancer or hypoparathyroidism. |
| Patient Advice | Take ORTHO-EST exactly as prescribed; do not increase dose or frequency without consulting your doctor. · If you have a uterus, you must also take a progestin to protect against endometrial cancer risk. · Report any unusual vaginal bleeding, breast lumps, or changes in discharge promptly. · Avoid smoking while taking estrogen therapy; smoking increases risk of serious cardiovascular events. · Notify your healthcare provider if you develop symptoms of blood clot: sudden leg pain/swelling, chest pain, shortness of breath, or vision changes. · This medication does not prevent pregnancy; use appropriate contraception unless advised otherwise. · Store at room temperature away from moisture and heat. |